Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Wasatch Clinical Research LLC

Neither a doctor nor a teaching hospital

Research payments

$3,260,022

814 payments

Through program year 2025, Wasatch Clinical Research LLC is reported as receiving $3,260,022 in research payments, across 814 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $153,700 50
2024 Research $390,679 143
2023 Research $406,621 126
2022 Research $865,441 189
2021 Research $577,697 79
2020 Research $575,605 199
2019 Research $290,279 28

Breakdown

Who paid Research payments · program years 2019–2025
  1. Genentech, Inc. $940,167 65 payments
  2. Pfizer Inc. $613,888 166 payments
  3. Biohaven Pharmaceutical Holding Company Ltd. $279,839 88 payments
  4. Sebela Pharmaceuticals Inc. $247,811 40 payments
  5. Averitas Pharma Inc. $227,833 89 payments
  6. Eisai Inc. $185,669 143 payments
  7. Sumitomo Pharma America, Inc. $129,409 47 payments
  8. Endo Pharmaceuticals Inc. $123,691 29 payments
  9. Braintree Laboratories, Inc. $114,439 28 payments
  10. H. Lundbeck A S $98,670 47 payments
Studies the money was for Research payments · program years 2019–2025
  1. Gantenerumab in Early Ad $665,341 31 payments
  2. A Phase 3 Randomized Doubleblinded Placebocontrolled Trial to Evaluate the Efficacy and Safety of A Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine in Infants Born to Women Vaccinated During Pregnancy $359,084 50 payments
  3. Postgraduate Roll Over Study $274,827 34 payments
  4. A Phase 3, Prospective, Multi-Center, Single-Arm, Open-Label Study to Evaluate VeraCept, a Long-Acting Reversible Intrauterine Contraceptive for Contraceptive Efficacy, Safety, and Tolerability $266,757 48 payments
  5. An Interventional Phase III Doubleblind Randomized Controlled Parallelgroup Multisite Clinical Trial Evaluating the Efficacy and Safety of Qutenza in Subjects With Postsurgical Neuropathic Pain $227,833 89 payments
  6. A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease $185,669 143 payments
  7. A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis $105,477 26 payments
  8. A Phase 2, Double-blind, Randomized, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of EN3835 vs Placebo in the Treatment of Plantar Fibromatosis $92,469 21 payments
  9. A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention $83,410 29 payments
  10. Phase 3 Multicenter Randomized Double-blindGroup Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents = 6 to <18 Years of Age $79,977 26 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record